SAN DIEGO, CA - October 28, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a leader in computational enzyme engineering and green chemistry innovation, is pleased to announce its successful participation in the Enzyme Engineering XXVIII Conference, held from September 15-19, 2025, in Helsingor, Denmark.
Organized by Engineering Conferences International (ECI), this prestigious biennial event brought together the world’s leading scientists, innovators, and industry pioneers to discuss the latest advancements in enzyme design, biocatalysis, and synthetic biology. The conference served as a platform for sharing breakthroughs that are shaping the future of sustainable manufacturing and green chemistry.
Quantumzyme’s participation highlighted its commitment to advancing the field of computational biocatalysis. The company showcased its cutting-edge innovations in enzyme-driven synthesis of APIs, including its recently published ibuprofen patent (US20250146029A1), which details a novel enzymatic pathway for producing ibuprofen - marking a significant milestone in eco-friendly pharmaceutical manufacturing.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated that “Participating in Enzyme Engineering XXVIII was a tremendous opportunity for Quantumzyme to share our vision and engage with global thought leaders in enzyme innovation. The discussions and collaborations initiated during this event reinforce our mission to accelerate the adoption of sustainable biocatalytic solutions worldwide.”
Quantumzyme’s proprietary QZyme Workbench™ platform integrates quantum mechanics, artificial intelligence, and molecular modeling to design next-generation enzymes for diverse industrial applications. The company’s involvement in this global forum reflects its growing reputation as a key innovator in green chemistry and computational enzyme design.
For more information about the conference, visit ECI Enzyme Engineering XXVIII (https://www.engconf.org/).
For the most current information and updates, please visit our website at www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
